News

Infectious Disease Advisor3h
FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
FDA’s new approach raises questions about fall COVID vaccine availability
Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or ...
FOX 32 Chicago3h
FDA will limit approval for seasonal COVID vaccines: What to know
Healthy younger adults and children will no longer be automatically approved for annual COVID-19 vaccines under a new policy from the FDA.
Victoria Advocate4h
FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
Managed Healthcare Executive4h
Concerns Grow Over Potential Delays in FDA Drug Approvals Amid Government Cuts
In this final interview of a three-part video series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD ...